Tofacitinib for Psoriatic Arthritis After Adalimumab
Author Information
Author(s): Gladman Dafna D., Nash Peter, Mease Philip J., FitzGerald Oliver, Duench Stephanie, Cadatal Mary Jane, Masri Karim R.
Primary Institution: University of Toronto
Hypothesis
Can patients with psoriatic arthritis safely switch from adalimumab to tofacitinib without a washout period?
Conclusion
Tofacitinib efficacy and safety were similar in patients who switched from adalimumab to tofacitinib and those who continued tofacitinib, indicating a direct switch is feasible.
Supporting Evidence
- 180 patients were included in the analysis.
- Patients who switched maintained similar efficacy outcomes.
- Safety profiles were comparable between the two treatment groups.
- Most patients who responded to adalimumab also responded to tofacitinib after switching.
Takeaway
This study shows that people with psoriatic arthritis can switch from one medicine to another without waiting, and it still works well.
Methodology
Patients received either tofacitinib or adalimumab in a Phase 3 study and then switched to tofacitinib in a long-term extension study.
Potential Biases
Selection bias may have occurred as only patients who completed the Phase 3 study were included.
Limitations
The analysis was post hoc, the sample size was small, and the timeframe was short.
Participant Demographics
{"age":{"median":48,"range":"23-72"},"gender_distribution":{"female_percentage":50.6},"ethnicity":{"white_percentage":97.8}}
Statistical Information
Statistical Significance
p<0.05
Digital Object Identifier (DOI)
Want to read the original?
Access the complete publication on the publisher's website